Skip Navigation LinksHome > January 2014 - Volume 9 - Issue 1 > Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination wi...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0000000000000027
Brief Reports

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

Chiappori, Alberto MD*; Williams, Charles MD; Northfelt, Donald W. MD; Adams, John W. MD; Malik, Shakun MD§; Edelman, Martin J. MD; Rosen, Peter MD; Van Echo, David A. MD#; Berger, Mark S. MD**; Haura, Eric B. MD*

Collapse Box


Introduction: The proapoptotic small-molecule pan–Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non–small-cell lung cancer (NSCLC).

Methods: Obatoclax was administered with docetaxel in patients with relapsed or refractory NSCLC— docetaxel as a 1-hour infusion on day 1 and obatoclax as a 24-hour infusion on days 1 and 2—every 3 weeks for up to eight cycles. Four dose levels were evaluated in phase 1 (level 1: docetaxel 55 mg/m2 × 1 and obatoclax 30 mg × 2; levels 2–4: docetaxel 75 mg/m2 and obatoclax 30 mg, 45 mg, or 60 mg × 2) to identify dose-limiting toxicity and a phase 2 dose. In phase 2, response and tolerability were evaluated.

Results: Eighteen patients were included in phase 1. Two dose-limiting toxicities occurred during cycle 1: one febrile neutropenia each at dose levels 3 and 4. Maximum tolerated dose was not reached; 32 patients (including 3 from phase 1) were treated in phase 2 with docetaxel 75 mg/m2 and obatoclax 60 mg (median 2 cycles). Three patients (11%) had partial responses in phase 2; two demonstrated stable disease lasting 12 weeks or more. Median duration of response was 4.8 months. Overall, median progression-free survival was 1.4 months. Neutropenia (31%), febrile neutropenia (16%), and dyspnea (19%) were the most common grade 3/4 adverse events observed.

Conclusions: Combined obatoclax mesylate plus docetaxel is tolerable in patients with NSCLC, but response was minimal and neutropenia was a common adverse event.

Copyright © 2014 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer.


Article Tools


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Other Ways to Connect



Visit on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.